- Home
- ESLA vs DTIL Comparison
ESLA vs DTIL Comparison
Compare ESLA & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESLA
- DTIL
- Stock Information
- Founded
- ESLA 2021
- DTIL 2006
- Country
- ESLA United States
- DTIL United States
- Employees
- ESLA N/A
- DTIL N/A
- Industry
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- ESLA Health Care
- DTIL Health Care
- Exchange
- ESLA Nasdaq
- DTIL Nasdaq
- Market Cap
- ESLA 48.9M
- DTIL 55.3M
- IPO Year
- ESLA N/A
- DTIL 2019
- Fundamental
- Price
- ESLA $2.92
- DTIL $6.18
- Analyst Decision
- ESLA Strong Buy
- DTIL Strong Buy
- Analyst Count
- ESLA 1
- DTIL 2
- Target Price
- ESLA $16.00
- DTIL $47.00
- AVG Volume (30 Days)
- ESLA 492.9K
- DTIL 188.7K
- Earning Date
- ESLA 11-13-2025
- DTIL 11-03-2025
- Dividend Yield
- ESLA N/A
- DTIL N/A
- EPS Growth
- ESLA N/A
- DTIL N/A
- EPS
- ESLA N/A
- DTIL N/A
- Revenue
- ESLA N/A
- DTIL $698,000.00
- Revenue This Year
- ESLA N/A
- DTIL N/A
- Revenue Next Year
- ESLA N/A
- DTIL $135.19
- P/E Ratio
- ESLA N/A
- DTIL N/A
- Revenue Growth
- ESLA N/A
- DTIL N/A
- 52 Week Low
- ESLA $0.70
- DTIL $3.61
- 52 Week High
- ESLA $3.15
- DTIL $8.82
- Technical
- Relative Strength Index (RSI)
- ESLA 65.89
- DTIL 43.85
- Support Level
- ESLA $2.20
- DTIL $6.18
- Resistance Level
- ESLA $3.15
- DTIL $8.77
- Average True Range (ATR)
- ESLA 0.43
- DTIL 0.66
- MACD
- ESLA 0.03
- DTIL -0.21
- Stochastic Oscillator
- ESLA 83.21
- DTIL 4.00
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.